Nabriva Therapeutics plc
NBRVF
$0.0001
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -12.06M | -8.70M | -22.78M | -11.51M | -11.07M |
| Total Depreciation and Amortization | 18.00K | 21.00K | 25.00K | 37.00K | 77.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.80M | 1.37M | 4.45M | 628.00K | 177.00K |
| Change in Net Operating Assets | 4.75M | 1.70M | 16.68M | 4.67M | -2.22M |
| Cash from Operations | 511.00K | -5.62M | -1.63M | -6.18M | -13.04M |
| Capital Expenditure | 0.00 | -3.00K | -9.00K | -103.00K | -64.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -50.00K | -- | 2.00K | -1.00K | -52.00K |
| Cash from Investing | -50.00K | -3.00K | -7.00K | -104.00K | -116.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00 | -4.85M | -998.00K | -974.00K | -949.00K |
| Issuance of Common Stock | -- | -- | 380.00K | 2.16M | 801.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 1.00K | -41.00K | -82.00K | -644.00K |
| Cash from Financing | 0.00 | -4.85M | -659.00K | 1.11M | -792.00K |
| Foreign Exchange rate Adjustments | -127.00K | -143.00K | 60.00K | -222.00K | 152.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 334.00K | -10.62M | -2.23M | -5.40M | -13.80M |